HCM Hutchison China MediTech Limited

25
-1.19  -5%
Previous Close 26.19
Open 24.89
Price To Book 9.92
Market Cap 3,452,873,825
Shares 138,114,953
Volume 184,703
Short Ratio
Av. Daily Volume 244,046
Stock charts supplied by TradingView

NewsSee all news

  1. Chi-Med to announce 2019 Final Results on Tuesday, March 3, 2020 – adjustment to announcement and presentation logistics due to travel restrictions

    LONDON, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Further to its announcement dated January 31, 2020, Hutchison China MediTech Limited ("Chi-Med") (NASDAQ:HCM) announced that its final results for the year ended December 31,

  2. Chi-Med Highlights Updated Phase II Savolitinib / Imfinzi® Combination Data in Advanced Papillary Renal Cell Carcinoma at 2020 ASCO Genitourinary Cancers Symposium

    LONDON, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited ("Chi-Med") (NASDAQ:HCM) today announced the availability of updated results from the Phase II CALYPSO study of the savolitinib / Imfinzi®

  3. Chi-Med Announces the Exercise of Underwriters' Over-allotment Option for Public Offering of ADSs

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION LONDON, Feb. 06,

  4. Chi-Med to Announce 2019 Final Results

    LONDON, Jan. 31, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited ("Chi-Med") (NASDAQ:HCM) will announce its final results for the year ended December 31, 2019 on Tuesday, March 3, 2020 at 7:00 am Greenwich

  5. Chi-Med Announces Pricing of US$110 Million Public Offering of ADSs

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION LONDON, Jan. 23, 2020 (GLOBE

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/1b trial initiation announced October 4, 2019.
HMPL-523
Indolent Non-Hodgkin lymphoma (NHL)
Phase 1/1b trial to be initiated 2H 2019.
HMPL-689
Indolent Non-Hodgkin lymphoma (NHL)
Phase 3 China trial stopped early. Primary endpoint met.
Savolitinib - SANET-p
Neuroendocrine Tumors
Phase 1/1b data be presented at ESMO 2019 noted ORR of 13.3% and DCR of 73.3%. Phase 2/3 trial to be initiated 1H 2020.
Surufatinib
Pancreatic neuroendocrine tumors
Phase 2/3 trial to be initiated 1H 2020.
Fruquintinib
Colorectal cancer
Phase 2 full data from papillary renal cell carcinoma cohort presented at ASCO-GU 2020.
Savolitinib + Imfinzi (CALYPSO)
Renal cell carcinoma (RCC)
Phase 2 interim analysis due 1H 2020.
Savolitinib (SAVANNAH)
Non-small cell lung cancer (NSCLC)
Phase 2 initiation announced January 13, 2020.
Surufatinib and Tuoyi
Solid Tumors

Latest News

  1. Chi-Med to announce 2019 Final Results on Tuesday, March 3, 2020 – adjustment to announcement and presentation logistics due to travel restrictions

    LONDON, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Further to its announcement dated January 31, 2020, Hutchison China MediTech Limited ("Chi-Med") (NASDAQ:HCM) announced that its final results for the year ended December 31,

  2. Chi-Med Highlights Updated Phase II Savolitinib / Imfinzi® Combination Data in Advanced Papillary Renal Cell Carcinoma at 2020 ASCO Genitourinary Cancers Symposium

    LONDON, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited ("Chi-Med") (NASDAQ:HCM) today announced the availability of updated results from the Phase II CALYPSO study of the savolitinib / Imfinzi®

  3. Chi-Med Announces the Exercise of Underwriters' Over-allotment Option for Public Offering of ADSs

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION LONDON, Feb. 06,

  4. Chi-Med to Announce 2019 Final Results

    LONDON, Jan. 31, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited ("Chi-Med") (NASDAQ:HCM) will announce its final results for the year ended December 31, 2019 on Tuesday, March 3, 2020 at 7:00 am Greenwich

  5. Chi-Med Announces Pricing of US$110 Million Public Offering of ADSs

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION LONDON, Jan. 23, 2020 (GLOBE

  6. Chi-Med Announces Proposed Public Offering of ADSs

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION LONDON, Jan. 21, 2020

  7. Chi-Med Announces that Surufatinib Phase III SANET-p Study Has Already Achieved its Primary Endpoint in Advanced Pancreatic Neuroendocrine Tumors in China and Will Stop Early

    LONDON, Jan. 20, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited ("Chi-Med") (NASDAQ:HCM) today announces that the independent Data Monitoring Committee ("IDMC") of the Phase III pivotal study of surufatinib

  8. Chi-Med Initiates a Phase II Trial of Surufatinib in Combination with Tuoyi in Patients with Advanced Solid Tumors

    LONDON, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited ("Chi-Med") (NASDAQ:HCM) has initiated a Phase II study in China of surufatinib in combination with Tuoyi (toripalimab) in patients with

  9. Chi-Med to Present at the 38th Annual JP Morgan Healthcare Conference

    LONDON, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited ("Chi-Med") (NASDAQ:HCM) today announces that Christian Hogg, Chief Executive Officer, will present at the 38th Annual JP Morgan Healthcare

  10. Chi-Med's New Drug Application for Surufatinib in Non-Pancreatic Neuroendocrine Tumors Granted Priority Review in China

    LONDON, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited ("Chi-Med") (NASDAQ:HCM) today announces that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration ("NMPA")

  11. Edison issues ADR update on Hutchison China MediTech (HCM)

    LONDON, UK / ACCESSWIRE / November 29, 2019 / Hutchison China MediTech (NASDAQ:HCM) has announced that Elunate (fruquintinib capsules) have been included in China's National Reimbursement Drug List (NRDL) by the

  12. Chi-Med's Elunate® (Fruquintinib Capsules) Included in the National Reimbursement Drug List in China

    LONDON, Nov. 28, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited ("Chi-Med") (NASDAQ:HCM) today announces that Elunate® (fruquintinib capsules), its national class 1 targeted anticancer drug for the treatment

  13. Chi-Med Announces Surufatinib Granted FDA Orphan Drug Designation for Pancreatic Neuroendocrine Tumors

    LONDON, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited ("Chi-Med") (NASDAQ:HCM) today announces that the U.S. Food and Drug Administration ("FDA") has granted Orphan Drug designation to surufatinib

  14. Chi-Med Highlights Oral Presentations at 2019 ESMO Asia Annual Meeting

    LONDON, Nov. 23, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited ("Chi-Med") (NASDAQ:HCM) will share analyses from two clinical studies of savolitinib and fruquintinib at the fifth European Society for

  15. Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations now available for On-Demand Viewing

    NEW YORK, Nov. 15, 2019 /PRNewswire/ -- Deutsche Bank today announced that the presentations from the November 13th and 14th Depositary Receipts Virtual Investor Conference ("dbVIC") are now available for

  16. Chi-Med Announces NDA Acceptance in China for Surufatinib in Non-Pancreatic Neuroendocrine Tumors

    LONDON, Nov. 11, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited ("Chi-Med") (NASDAQ:HCM) today announces that its New Drug Application ("NDA") for surufatinib for the treatment of patients with advanced

  17. International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on November 13th and 14th, 2019

    NEW YORK, Nov. 6, 2019 /CNW/ - Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference ("dbVIC") on November 13th and 14th, featuring live webcast presentations from

  18. Chi-Med highlights publication of Phase II data showing promising efficacy for Savolitinib in MET-amplified gastric cancers

    LONDON, Oct. 17, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited ("Chi-Med") (NASDAQ:HCM) today highlighted the publication of results from the Phase II VIKTORY (targeted agent eValuation In gastric cancer

  19. Edison issues ADR update on Hutchison China MediTech (HCM)

    LONDON, UK / ACCESSWIRE / October 10, 2019 / Hutchison China MediTech (NASDAQ:HCM) presented robust SANET-ep Phase III China data at ESMO 2019 on surufatinib in non-pancreatic neuroendocrine tumors (NET). The data

  20. Innovent and Chi-Med Expand Global Collaboration to Evaluate the Combination of Sintilimab and Surufatinib in Solid Tumors

    SUZHOU, China and LONDON, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801) and Hutchison China MediTech Limited ("Chi-Med") (NASDAQ:HCM) today announced the expansion of their

  21. Innovent and Chi-Med Expand Global Collaboration to Evaluate the Combination of Sintilimab and Surufatinib in Solid Tumors

    SUZHOU, China and LONDON, Oct. 10, 2019 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801) and Hutchison China MediTech Limited ("Chi-Med") (NASDAQ:HCM) today announced the expansion of

  22. Chi-Med Initiates an International Phase I/Ib Trial of HMPL-523 in Patients with Advanced Relapsed or Refractory Lymphoma

    LONDON, Oct. 04, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited ("Chi-Med") (NASDAQ:HCM) has initiated an international Phase I/Ib study of HMPL-523, its novel spleen tyrosine kinase ("Syk") inhibitor, in

  23. CK Hutchison prices offering of Chi-Med share capital enabling deconsolidation and confirms its intention to hold Chi-Med as a strategic investment for the long term

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION LONDON, Sept. 30, 2019

  24. CK Hutchison offers 1.3% of Chi-Med's share capital aiming to deconsolidate and hold Chi-Med as a strategic investment for the long term

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION LONDON, Sept. 30, 2019

  25. Chi-Med to Discuss Surufatinib Phase III and U.S. Phase I/Ib Efficacy and Safety Data Presented at the 2019 ESMO Annual Meeting

    – Surufatinib achieved primary endpoint, reducing the risk of progression or death by 67% in patients with non-pancreatic neuroendocrine tumors ("NET") in the Phase III SANET-ep study – – Preparations underway for the

  26. Chi-Med Highlights Presentation of Clinical Data from the Successful SANET-ep Phase III Trial at ESMO Annual Meeting

    – Late-Breaking Abstract of the positive SANET-ep Phase III trial of surufatinib in patients with non-pancreatic neuroendocrine tumors ("NET") to be presented – – Conference call and webcast with lead trial

  27. Chi-Med Highlights Oral Presentations at 2019 CSCO Annual Meeting

    LONDON, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited ("Chi-Med") (NASDAQ:HCM) shares additional analyses from three completed and ongoing clinical studies of fruquintinib and savolitinib at the